
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc is strategically positioned in the clinical-stage pharmaceutical sector, focusing on complex treatments for cancer, particularly targeting recurrent glioblastoma and leptomeningeal metastases. The company's candidate, rhenium (186Re) obisbemeda, has shown promising potential for reducing healthcare costs related to leptomeningeal metastases by approximately 40%, enhancing its value proposition to payers and health systems amid a challenging treatment landscape. Additionally, the FDA's constructive feedback for accelerated approval pathways for Reyobiq underscores the significant unmet medical need in these indications, potentially driving increased adoption and reimbursement opportunities for the company.
Bears say
Plus Therapeutics Inc. faces significant financial challenges, as indicated by its recent downgrade and lowered price target, reflecting a potentially strained capital market environment linked to a reverse stock split. The company reported a substantial operating loss of $15.3 million for the full year 2025, coupled with a net loss of $22.4 million, raising concerns about its financial sustainability and operational efficiency. Despite ending 2025 with $13.1 million in cash and investments, the continuity of funding and the impact of upcoming warrant exercises contribute to an uncertain outlook for the company's liquidity and overall financial health.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares